{"@context":"https://schema.org","@type":"DietarySupplement","id":"https://nutripedia.co.uk/items/probiotics","url":"https://nutripedia.co.uk/items/probiotics","name":"Probiotics","category":"Wellness","tagline":"Live bacteria to support gut health and immune function.","verdict":"mixed","evidenceRating":3,"verdictSummary":"Benefits are highly strain-specific. Good evidence for certain strains in IBS, antibiotic-associated diarrhoea, and immune support. Generic multi-strain products often lack clinical backing.","dosage":{"recommended":"1–10","unit":"billion CFU","timing":"With or before meals","notes":"Strain matters more than dose. Look for specific strains with clinical evidence for your goals."},"keyBenefits":["May improve IBS symptoms (strain-dependent)","Reduces antibiotic-associated diarrhoea","Supports immune system modulation","Potential mood benefits via gut-brain axis"],"warnings":["Benefits are strain-specific — not all probiotics are equal","Immunocompromised individuals should consult a doctor","Initial bloating and gas may occur","Refrigeration may be required for some products"],"evidenceSummary":null,"dosing":null,"safety":null,"whoMightBenefit":[],"whoShouldAvoid":[],"regulatoryNotes":null,"faqs":[{"question":"What does the research say about probiotics and IBS?","answer":"A 2018 meta-analysis of 53 RCTs (n=4,595, PMID: 30267869) found probiotics significantly improved IBS global symptoms compared with placebo (RR 0.79). Evidence is strain-specific: Bifidobacterium infantis 35624 (Align) and multi-strain preparations such as VSL#3 have the most consistent RCT support. NICE guideline CG61 acknowledges probiotics may be recommended for IBS symptom management if used for at least 4 weeks. Effect on bloating and abdominal pain was modest; constipation-predominant and diarrhoea-predominant IBS showed somewhat different strain responses."},{"question":"What dosage ranges have been studied for probiotics?","answer":"Probiotic doses in clinical trials are expressed in colony-forming units (CFU) and typically range from 1 billion (10⁹) to 450 billion (4.5×10¹¹) CFU per day. Most IBS and immune trials used 1–10 billion CFU/day. VSL#3, the highest-dose multi-strain product studied in RCTs, contains 450–900 billion CFU per sachet. For antibiotic-associated diarrhoea prevention, trials have used 2–20 billion CFU/day of Lactobacillus rhamnosus GG or Saccharomyces boulardii. Minimum effective doses are strain-specific — CFU count alone does not determine efficacy."},{"question":"What side effects have been reported in trials of probiotics?","answer":"In healthy adults, probiotics have an excellent safety profile in RCTs with side effects comparable to placebo. Initial bloating and increased flatulence are the most commonly reported mild adverse events, typically resolving within 1–2 weeks of use. Serious adverse events are rare and primarily reported in immunocompromised individuals; the FDA and EFSA have issued guidance that probiotics should be used with caution in patients with central venous catheters, short bowel syndrome, or severe immunodeficiency, where bacteraemia and fungaemia risk is elevated."},{"question":"Is there evidence for probiotics with antibiotic treatment?","answer":"A 2017 Cochrane review (PMID: 29257353, 31 RCTs, n=8,672) found probiotics reduced C. difficile-associated diarrhoea by approximately 60% versus placebo (RR 0.40). Trials report that Lactobacillus rhamnosus GG and Saccharomyces boulardii CNCM I-745 are the most evidence-supported strains. The British Society of Gastroenterology 2021 guidelines note that probiotic co-administration during antibiotic courses is reasonable for prevention of AAD, particularly in older adults or those with prior AAD history. Most trials administered probiotics within 24–48 hours of antibiotic initiation."},{"question":"What strains of probiotics have the strongest evidence base?","answer":"Strain specificity is critical — different strains have distinct mechanisms and clinical evidence. Lactobacillus rhamnosus GG has the most published RCT evidence overall, including antibiotic-associated diarrhoea, paediatric gastroenteritis, and immune support. Saccharomyces boulardii CNCM I-745 (a yeast) has strong evidence for AAD and C. difficile prevention. Bifidobacterium infantis 35624 has RCT evidence for IBS-D. VSL#3 (multi-strain: 8 strains) has RCT support for IBS and ulcerative colitis remission maintenance. Generic multi-strain products without strain identification on the label cannot be directly compared with published trial data."},{"question":"What do NHS and EFSA say about probiotics?","answer":"The NHS website advises that probiotics are generally safe for most people and may help with some digestive problems, directing patients to look for NICE-recommended strains for specific conditions such as IBS (CG61). EFSA has not authorised any specific health claim for probiotic bacteria — all claim applications referencing named strains have been rejected due to insufficient substantiation at the specific strain level. EFSA requires strain-specific clinical evidence for health claim authorisation; this remains an ongoing regulatory hurdle for the probiotic industry in Europe."},{"question":"What does the research say about probiotics and mental health?","answer":"The gut-brain axis is an active area of investigation. A meta-analysis of 9 RCTs (n=672, PMID: 27509521) found psychobiotics produced a statistically significant but modest reduction in depression scores (SMD −0.34). A 2019 meta-analysis (n=1,033) found significant reductions in both anxiety and depression scales with multi-strain preparations. Study quality is generally low-to-moderate; strain-specific effects are not yet established. Most trials used Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 in combination. Larger, higher-quality trials are ongoing."}],"research":{"totalCount":15,"papers":[{"title":"Effects of Prebiotics and Probiotics on Symptoms of Depression and Anxiety in Clinically Diagnosed Samples: Systematic Review and Meta-analysis of Randomized Controlled Trials","year":2025,"journal":"Nutrition Reviews","doi":"10.1093/nutrit/nuae177","pmid":"39731509","url":"https://doi.org/10.1093/nutrit/nuae177","studyDesign":"meta-analysis","fields":[],"conclusion":"Systematic review and meta-analysis found probiotics demonstrated a significant reduction in depression symptoms in clinically diagnosed populations; prebiotics showed a non-significant trend toward benefit. Probiotics also produced moderate improvements in anxiety scores. Authors recommend probiotics as an adjunctive intervention alongside standard psychiatric treatment, with effects likely mediated via the gut-brain axis.","abstract":"","citationCount":0},{"title":"High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial (SPAADA)","year":2024,"journal":"Open Forum Infectious Diseases","doi":"10.1093/ofid/ofae615","pmid":"","url":"https://doi.org/10.1093/ofid/ofae615","studyDesign":"rct","fields":[],"conclusion":"Phase IV multicenter RCT (N=555) found high-dose multi-strain probiotic formulation significantly reduced AAD incidence versus placebo (9.2% vs 25.3%, p<0.001) in adults receiving broad-spectrum antibiotics. No clinically relevant differences in adverse events between groups. Results support high-dose multi-strain preparations for AAD prevention.","abstract":"","citationCount":0},{"title":"Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials","year":2024,"journal":"United European Gastroenterology Journal","doi":"10.1002/ueg2.12636","pmid":"39106167","url":"https://doi.org/10.1002/ueg2.12636","studyDesign":"meta-analysis","fields":[],"conclusion":"Overview of 22 systematic reviews and 45 RCTs (67 total studies) found probiotics beneficial for ulcerative colitis remission maintenance and pouchitis prevention, with multi-strain formulations appearing superior. No significant benefit was demonstrated for Crohn's disease. Safety profiles were comparable to placebo. Overall evidence certainty remained low.","abstract":"","citationCount":0},{"title":"World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics","year":2024,"journal":"Journal of Clinical Gastroenterology","doi":"10.1097/MCG.0000000000002002","pmid":"38885083","url":"https://doi.org/10.1097/MCG.0000000000002002","studyDesign":"position-stand","fields":[],"conclusion":"Updated WGO global practice guidelines provide strain- and indication-specific recommendations for probiotic and prebiotic use across gastroenterological conditions. Guidelines require at least one adequately powered double-blind RCT per strain-indication pair. Recommendations cover IBS, AAD, acute diarrhoea, H. pylori, pouchitis, and paediatric conditions.","abstract":"","citationCount":0},{"title":"Additive efficacy and safety of probiotics in the treatment of ulcerative colitis: a systematic review and meta-analysis","year":2024,"journal":"European Journal of Nutrition","doi":"10.1007/s00394-023-03307-5","pmid":"38446227","url":"https://doi.org/10.1007/s00394-023-03307-5","studyDesign":"meta-analysis","fields":[],"conclusion":"Meta-analysis of 13 RCTs (930 patients) found probiotic-assisted therapy was effective in inhibiting UC recurrence in patients in clinical remission, without increasing adverse events. For active UC, probiotics showed a trend toward improved remission induction but results were inconclusive. Multi-strain adjunctive approaches are recommended for remission maintenance.","abstract":"","citationCount":0},{"title":"Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?","year":2024,"journal":"Advances in Therapy","doi":"10.1007/s12325-024-02783-3","pmid":"38286962","url":"https://doi.org/10.1007/s12325-024-02783-3","studyDesign":"systematic-review","fields":[],"conclusion":"Timely administration of an adequately dosed probiotic — specifically S. boulardii CNCM I-745 or L. rhamnosus GG — at antibiotic initiation or within 48 hours can prevent or resolve antibiotic-associated dysbiosis and support microbiota resilience in children and adults. Strain specificity and early timing are critical determinants of efficacy.","abstract":"","citationCount":0},{"title":"Probiotics for the management of irritable bowel syndrome: a systematic review and three-level meta-analysis","year":2023,"journal":"International Journal of Surgery","doi":"10.1097/JS9.0000000000000658","pmid":"37565634","url":"https://doi.org/10.1097/JS9.0000000000000658","studyDesign":"meta-analysis","fields":[],"conclusion":"Meta-analysis of 72 RCTs demonstrated probiotics significantly improved global IBS symptom severity, abdominal pain, and quality of life versus placebo. Treatment duration and strain type were significant moderators; shorter interventions and Bacillus-based formulations yielded the largest effect sizes.","abstract":"","citationCount":0},{"title":"Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis","year":2023,"journal":"Gastroenterology","doi":"10.1053/j.gastro.2023.07.018","pmid":"37541528","url":"https://doi.org/10.1053/j.gastro.2023.07.018","studyDesign":"meta-analysis","fields":[],"conclusion":"Analysis of 82 RCTs (10,332 patients) found moderate-certainty evidence that E. coli strains benefit global IBS symptoms; evidence for most other probiotic interventions was low to very low certainty. No significant safety concerns were identified. Evidence is insufficient to recommend specific strains as standard care.","abstract":"","citationCount":0},{"title":"Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants","year":2023,"journal":"Cochrane Database of Systematic Reviews","doi":"10.1002/14651858.CD005496.pub6","pmid":"37493095","url":"https://doi.org/10.1002/14651858.CD005496.pub6","studyDesign":"meta-analysis","fields":[],"conclusion":"Cochrane review of 60 RCTs (11,156 infants) found probiotics may reduce necrotising enterocolitis risk (RR 0.54) and probably reduce all-cause mortality slightly (RR 0.77) in very preterm or very low birth weight infants. Evidence certainty was low to moderate; little or no effect was observed in extremely preterm infants. Further large trials are needed before routine clinical implementation.","abstract":"","citationCount":0},{"title":"Emerging issues in probiotic safety: 2023 perspectives","year":2023,"journal":"Gut Microbes","doi":"10.1080/19490976.2023.2185034","pmid":"36919522","url":"https://doi.org/10.1080/19490976.2023.2185034","studyDesign":"position-stand","fields":[],"conclusion":"International expert panel concluded that established practices adequately address traditional probiotic safety for healthy populations. Whole genome sequencing should be standard for safety assessment. Probiotic use requires caution in immunocompromised, critically ill, preterm, or elderly individuals due to rare but serious risks including bacteraemia and fungaemia. Rigorous adverse event reporting was recommended.","abstract":"","citationCount":0},{"title":"Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications","year":2023,"journal":"Journal of Pediatric Gastroenterology and Nutrition","doi":"10.1097/MPG.0000000000003633","pmid":"36219218","url":"https://doi.org/10.1097/MPG.0000000000003633","studyDesign":"position-stand","fields":[],"conclusion":"ESPGHAN position paper provides strain-specific recommendations for paediatric GI disorders including acute gastroenteritis, antibiotic-associated diarrhoea, nosocomial diarrhoea, NEC, H. pylori, functional abdominal pain, and colic. L. rhamnosus GG and S. boulardii received the strongest recommendations. Further research needed to define optimal dose and timing for most indications.","abstract":"","citationCount":0},{"title":"Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis","year":2022,"journal":"Frontiers in Cellular and Infection Microbiology","doi":"10.3389/fcimb.2022.859967","pmid":"35433498","url":"https://doi.org/10.3389/fcimb.2022.859967","studyDesign":"meta-analysis","fields":[],"conclusion":"Network meta-analysis of 43 RCTs (5,531 patients) found Bacillus coagulans had the highest probability of being the optimal species for IBS symptom relief, global symptoms, abdominal pain, bloating, and straining. Eight-week treatment duration was associated with greater efficacy. Probiotic dose did not significantly influence outcomes.","abstract":"","citationCount":0},{"title":"Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome","year":2022,"journal":"World Journal of Gastroenterology","doi":"10.3748/wjg.v28.i7.732","pmid":"35317278","url":"https://doi.org/10.3748/wjg.v28.i7.732","studyDesign":"cohort","fields":[],"conclusion":"Prospective multicenter observational study found that 30 days of B. longum 35624 (one capsule/day) produced a significant reduction in IBS symptom severity from baseline; 57% of patients moved to lower severity categories or achieved remission. Quality of life improved and 63.8% of patients reported treatment satisfaction. No serious adverse events were recorded.","abstract":"","citationCount":0},{"title":"Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis","year":2021,"journal":"BMJ Open","doi":"10.1136/bmjopen-2020-043054","pmid":"34385227","url":"https://doi.org/10.1136/bmjopen-2020-043054","studyDesign":"meta-analysis","fields":[],"conclusion":"Co-administration of probiotics with antibiotics reduced the risk of antibiotic-associated diarrhoea by 37% across 42 studies (11,305 participants). Lactobacillus and Bifidobacterium species showed greatest effectiveness. Higher-dose formulations demonstrated superior protective effects compared to lower doses. Evidence quality was rated as moderate.","abstract":"","citationCount":0},{"title":"Probiotics for the Prevention of Antibiotic-associated Diarrhea in Adults: A Meta-Analysis of Randomized Placebo-Controlled Trials","year":2020,"journal":"Journal of Clinical Gastroenterology","doi":"10.1097/MCG.0000000000001464","pmid":"33234881","url":"https://doi.org/10.1097/MCG.0000000000001464","studyDesign":"meta-analysis","fields":[],"conclusion":"Probiotics reduced antibiotic-associated diarrhoea incidence by 38% across 36 RCTs (9,312 participants). Initiating probiotics within two days of antibiotic prescription was most beneficial. No statistically significant increase in adverse events was observed, supporting safety in adults without immunodeficiency.","abstract":"","citationCount":0}]},"machineReadable":{"markdownUrl":"https://nutripedia.co.uk/items/probiotics/markdown","jsonUrl":"https://nutripedia.co.uk/items/probiotics/json","llmsTxt":"https://nutripedia.co.uk/llms.txt"},"disclaimer":"Informational supplement research only. Not medical advice. Consult a qualified healthcare professional before taking supplements.","lastReviewed":"2026-04-20T00:00:00.000Z","updatedAt":"2026-04-20T00:00:00.000Z"}